Role of advanced glycation end products in diabetic nephropathy.
about
Vitamin B and its derivatives for diabetic kidney diseaseVitamin B and/or its derivatives for diabetic kidney diseasePrevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complicationDrug Targets for Oxidative Podocyte Injury in Diabetic NephropathyHistological changes of kidney in diabetic nephropathyMetabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom controlEffect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-AnalysisAdvanced glycation end products and diabetic complicationsInsight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profilingDiabetic Kidney Disease: Pathophysiology and Therapeutic TargetsMechanisms of corneal tissue cross-linking in response to treatment with topical riboflavin and long-wavelength ultraviolet radiation (UVA).FOXO transcription factors: their clinical significance and regulation.Advanced glycation end products in idiopathic frozen shouldersExpression of toll-like receptor 2 in glomerular endothelial cells and promotion of diabetic nephropathy by Porphyromonas gingivalis lipopolysaccharide.Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling.Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus.C-peptide and diabetic kidney disease.Angiotensin-(1-7) abolishes AGE-induced cellular hypertrophy and myofibroblast transformation via inhibition of ERK1/2.Expression of Toll-Like Receptor 4 in Glomerular Endothelial Cells under Diabetic Conditions.A glimpse of matrix metalloproteinases in diabetic nephropathy.Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man.Emerging drugs for renal failure.Administration of Danhong Injection to diabetic db/db mice inhibits the development of diabetic retinopathy and nephropathy.Immunization of AGE-modified albumin inhibits diabetic nephropathy progression in diabetic miceAssessment of carotid arterial wall elasticity in type 2 diabetes mellitus patients with microalbuminuria by real-time ultrasound elastography.Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney.Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy.Assessment of carotid atherosclerosis in type 2 diabetes mellitus patients with microalbuminuria by high-frequency ultrasonography.A glimpse of various pathogenetic mechanisms of diabetic nephropathy.Oxidative stress in diabetic nephropathy.Metabolomics in diabetic complications.Tetrahydroindenoindole inhibits the progression of diabetes in micePuerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats.Papaverine increases human serum albumin glycation.Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy.Glycation in diabetic nephropathy.An update on peritoneal dialysis solutions.The renal endothelium in diabetic nephropathy.The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach.
P2860
Q24186641-6B2C106E-C33B-45A8-9424-83A32098D0BFQ24236375-F1D9DD67-9435-4FAD-8A32-1B62967149F3Q26751110-D25143CD-C636-4C91-8098-E81C5EDC82E3Q26769787-20FF135B-2E0C-4B74-BFD1-2A4A007813D6Q26773633-E24A5296-E3C0-4447-BAA8-F03154693C25Q26852079-C8D153F5-1289-404D-85A7-F1A694CA2477Q26852444-C73E2C62-6024-49F5-A1FB-D808B273B143Q27687501-AE4F281A-C377-4ADE-9ED1-49E6BE039FDAQ28076999-4EC4002D-C0BA-444B-922C-276E8D301DFEQ28086840-8F96B8B4-64C1-4B63-B1B3-E34C9D9283B1Q33488877-2A87F038-0196-40BA-A22B-6F109237AF94Q33594004-3C05C2BA-EABF-4153-8161-F9BEF446B11EQ33596312-62EB004D-4B89-4509-8442-57FFE6875BA0Q33623473-501DED51-E7E1-4239-9915-0BCF4EB8169DQ33711306-82D33DCF-F63D-4E98-8F03-376B3EF53908Q33999815-EA9878D3-CD45-412F-88D1-733DD39811D8Q34540591-466A7799-A22E-46D7-9669-ABF102295CC1Q34623871-FE82B9D5-7536-4198-8E20-D1D96965F866Q34647622-6E19EB32-D2B7-423F-A107-806975BAA965Q34796034-5654E110-B4EE-448B-AA83-1174DC68CC60Q35237455-F1B6C299-3F14-482C-A7EC-BBC8DAE5670FQ35602657-9CDFCE7C-487D-42B7-95C7-0E8FCA2C824BQ35711564-C2E5A852-7158-4767-A24A-CC9BB2F6CC89Q35766118-C3363BE1-7E1D-46C3-8AE5-25F589071B8FQ36014557-0B9888BE-6E3C-4A95-A80A-60DA1867F1B4Q36204022-441491ED-2E06-4032-B8EF-4B4A2CF8B19CQ36262407-9B4B8753-DCD3-40F0-ACB1-484F4C463F6EQ36312635-F49BEF0A-82C8-4DC7-8A80-99B39267C56BQ36729116-9C08FA1E-AA63-465C-B852-581A6BAEC24DQ36979205-D4888A9D-5BAD-4070-9D10-ABFF1711FCBAQ37003803-6E85815F-193A-44BA-A4E1-9ADF3DAD48FBQ37041169-8CB76F48-A4DA-4ADB-8EF8-825D9B416E62Q37070849-F26EFCB3-7434-47B9-B3D5-7BF1ED4FB097Q37484328-E2E664A7-8681-474B-AD73-D0A16515C041Q37582964-7A22AC2A-8866-4763-8C15-52E0403221A7Q37780781-F17EEEF0-E398-4657-97AF-4842FF8852D0Q37801858-2A5AD603-38F7-4530-8FCD-DA5F32C6FC8FQ37986357-F975CF84-0A50-4C74-838C-A2B9C5FC61ABQ38087656-95DE9A5C-0DD6-43DE-964B-0819ACDFDC42Q38241689-2DE6D63E-0A4B-4D28-BD79-84CCD8263827
P2860
Role of advanced glycation end products in diabetic nephropathy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Role of advanced glycation end products in diabetic nephropathy.
@ast
Role of advanced glycation end products in diabetic nephropathy.
@en
type
label
Role of advanced glycation end products in diabetic nephropathy.
@ast
Role of advanced glycation end products in diabetic nephropathy.
@en
prefLabel
Role of advanced glycation end products in diabetic nephropathy.
@ast
Role of advanced glycation end products in diabetic nephropathy.
@en
P1476
Role of advanced glycation end products in diabetic nephropathy
@en
P2093
Mark E Cooper
Matthew D Oldfield
P304
P356
10.1097/01.ASN.0000077413.41276.17
P433
P577
2003-08-01T00:00:00Z